Concizumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Concizumab. Educational only — not medical advice.
Labeled uses
Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors • hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors
Source: FDA labeling via NIH DailyMed (set 156f6404…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.